Summary:
- Denali Therapeutics, a biopharmaceutical company, has reported its financial results for the second quarter of 2025.
- The company's research and development efforts are focused on developing treatments for neurodegenerative diseases, such as Alzheimer's and Parkinson's.
- Denali Therapeutics has made progress in advancing its pipeline of drug candidates, including initiating new clinical trials and reporting positive data from ongoing studies.